ProfileGDS5678 / 1438228_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 15% 14% 14% 10% 14% 14% 14% 13% 14% 14% 14% 14% 14% 14% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.3885615
GSM967853U87-EV human glioblastoma xenograft - Control 22.3530314
GSM967854U87-EV human glioblastoma xenograft - Control 32.3547314
GSM967855U87-EV human glioblastoma xenograft - Control 42.2111110
GSM967856U87-EV human glioblastoma xenograft - Control 52.3114714
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.4040214
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.363714
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.3129713
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.3198114
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.340214
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.3345814
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.3283714
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.3461214
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.3437714